
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Pfizer Inc. has ended its research into sildenafil citrate (Viagra) as a treatment for female sexual arousal disorder (FSAD) after several large studies showed inconclusive efficacy.





